Determination of Skeletal Muscle Mass Index Values in the Turkish Population Using Dual Energy X-Ray Absorptiometry

NCT07510009 | Active Not Recruiting

• 1 other identifier: ACHBİLKENTAUBAYKUT003
• Study Type: observational
• Target: 82
• Locations: 1 country
• Sites: 1

Brief Summary

Sarcopenia is defined by the European Working Group on Sarcopenia in Older People (EWGSOP) as "a syndrome characterized by progressive and generalized loss of skeletal muscle mass and strength, carrying a risk of adverse outcomes such as physical disability, fractures, falls, impaired quality of life, and death." However, despite the severity of the disease, a single diagnostic criterion has not yet been established, and various guidelines have been proposed to standardize the diagnostic criteria and cut-off values. Current European Working Group on Sarcopenia in Older People (EWGSOP) recommendations focus on European populations and, where possible, the use of normative references from healthy young adults. Since measurements such as gait and muscle strength are height-dependent, the use of regional normative populations is recommended whenever possible. Currently, some cut-off points for the diagnosis of sarcopenia are arbitrary. The development of validated cut-off points will depend on normative data and their predictive value for endpoints. Further studies are needed to determine whether gender-specific and region-specific threshold values for the diagnosis of sarcopenia improve the prediction of sarcopenia outcomes. There are no studies in the literature on dual-energy x-ray absorptiometry cutoff values specific to the Turkish population. In our study, we aimed to define reference cutoff values for muscle mass, muscle strength, and calf circumference in Türkiye in order to improve the general applicability of EWGSOP criteria.

Conditions

Sarcopenia; Sarcopenia in Elderly

Keywords

sarcopenia; sarcopenia in elderly

Outcome Measures

Primary Outcomes (1)

• skeletal muscle mass index

  Skeletal muscle mass index: calculated by dividing the sum of the non-bone lean mass of the four extremities by height² (meters).

  At the start of the work

Secondary Outcomes (4)

• muscle strength

  at the start of the work

• walking speed test

  at the start of the work

• Calf circumference

  at the start of the work

• Mid-arm circumference

  at the start of the work

Study Arms (2)

young population

Ages 18-39

elderly population

Ages 65-99

Eligibility Criteria

• Age: 18 Years - 99 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

city hospital

You may qualify if:

• Having mental and physical capacity
• Being between 18-39 and 65-99 years of age
• Being able to ambulate independently or with support

You may not qualify if:

• Pregnancy
• Infection
• Pacemaker or metallic implant
• Peripheral circulatory disorder
• Known concomitant malignancy, end-stage organ failure
• Known concomitant central nervous system and/or peripheral nervous system disease
• History of genetic disease
• Coagulopathy
• Amputation
• Patients with a history of genetic disease
• Patients weighing \>120 kg

Sponsors & Collaborators

• Ankara City Hospital Bilkent: lead

Study Sites (1)

Ankara Bilkent City Hospital

Ankara, 06800, Turkey (Türkiye)

Location

Related Publications (1)

• Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyere O, Cederholm T, Cooper C, Landi F, Rolland Y, Sayer AA, Schneider SM, Sieber CC, Topinkova E, Vandewoude M, Visser M, Zamboni M; Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019 Jan 1;48(1):16-31. doi: 10.1093/ageing/afy169.

  PMID: 30312372 RESULT

MeSH Terms

Conditions

Sarcopenia

Condition Hierarchy (Ancestors)

Muscular Atrophy; Neuromuscular Manifestations; Neurologic Manifestations; Nervous System Diseases; Atrophy; Pathological Conditions, Anatomical; Pathological Conditions, Signs and Symptoms; Signs and Symptoms

Study Officials

• Ayşe U Baykut

  Ankara City Hospital Bilkent

  PRINCIPAL INVESTIGATOR

• Güldal F Yüzer Nakipoğlu

  Ankara City Hospital Bilkent

  STUDY CHAIR

• Zeynep S Güneş

  Ankara City Hospital Bilkent

  STUDY CHAIR

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Doctor

Study Record Dates

• First Submitted: March 28, 2026
• First Posted: April 3, 2026
• Study Start: June 30, 2024
• Primary Completion: June 30, 2025
• Study Completion: April 30, 2026
• Last Updated: April 8, 2026

Record last verified: 2026-04

Locations

TU (1)